A Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long-acting rhGH-HMC001 Conjugate in Treatment of Subjects Suffering From Adult Growth Hormone Deficiency (AGHD)

Trial Profile

A Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long-acting rhGH-HMC001 Conjugate in Treatment of Subjects Suffering From Adult Growth Hormone Deficiency (AGHD)

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2016

At a glance

  • Drugs Efpegsomatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Therapeutic Use
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 May 2015 Status changed from active, no longer recruiting to completed.
    • 13 Mar 2015 According to a Hanmi Pharmaceuticals media release, interim results were presented at the Endocrine Society conference (ENDO) 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top